Video

Dr. Brugarolas on rationale for targeting HIF2α in renal cell carcinoma

“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.

James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.

Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.